Kaleido Biosciences, Inc.KLDOOTCMARKET
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank13
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P13
Within normal range
vs 3Y Ago
-0.2x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2021 | -10.55% |
| Q3 2021 | -1.26% |
| Q2 2021 | 2.61% |
| Q1 2021 | 19.86% |
| Q4 2020 | -8.44% |
| Q3 2020 | 22.02% |
| Q2 2020 | -2.31% |
| Q1 2020 | -6.74% |
| Q4 2019 | -12.98% |
| Q3 2019 | -13.78% |
| Q2 2019 | 23.67% |
| Q1 2019 | -0.17% |
| Q4 2018 | 49.57% |
| Q3 2018 | 11.25% |
| Q2 2018 | 21.12% |
| Q1 2018 | 0.90% |
| Q4 2017 | 0.00% |